Laurence Katznelson
Publication Details
-
Endogenous NIS expression in triple-negative breast cancers.
Ann Surg Oncol. 2009; (4): 962-8
The sodium iodide symporter (NIS) mediates iodide transport into cells and has been identified in approximately 70% of breast cancers. Functional NIS expression raises the possibility of using (131)I for therapeutic targeting of tumor cells. Treatment of triple-negative breast cancers [estrogen/progesterone receptor-negative and HER2-negative (ER-/PR-/HER2-)] is primarily limited to chemotherapy. Our aim was to characterize NIS expression in this subset of tumors.
Help
Trial Administration